LUND, Sweden – As Cellevate published in the news on March 27, 2023, the company is one of the technology providers in the AdBIOPRO consortium with supplying nanofiber-based technology for Upstream AAV (adeno-associated virus), lentivirus and cell therapy bioproduction. The AdBIOBRO consortium today released the news about securing 112 mkr funding, which will enable AdBIOPRO to expand its activities over the next five years. This includes the development of continuous bioprocessing, advancements in bioprocessing towards cell and gene therapies, and the inclusion of new technologies.
This highly multi-disciplinary Centre gathers eight academic groups from KTH Royal Institute of Technology, Lund University, Karolinska Hospital, Karolinska Institutet and Linköping University, as well as 16 industrial partners. The industry partners are Alfa Laval, ArgusEye, AstraZeneca, BioInvent International, BioLamina, Cellcolabs, Cellevate, Cytiva, Erbi Biosystems, a company of Merck KGaA Darmstadt Germany, Magic Bioprocessing, Metenova, NorthX Biologics, Nyctea Technologies, TimeGate Instruments, Valneva and XNK Therapeutics.
Veronique Chotteau, Director of AdBIOPRO, was quoted in today´s news release by AdBIOPRO regarding the consortium’s new funding:” This is very exciting. We are now starting the next period, which consolidates our highly multi-disciplinary work within continuous bioprocessing introducing more Process Analytical Technology (PAT) to support digital twins, increasing bioprocessing towards cell and gene therapies and including new technologies. We are also very glad to see that many new partners from industry and academia, are joining the Centre, both developers of ATMPs, as well as providers of material and equipment to the field. We expand now our very successful collaborations within AdBIOPRO backed by fresh funding and considerable support from industrial competence.”
Further quotes from the news by AdBIOPRO and extracted from the evaluation of AdBIOPRO by the panel of international experts and generalists:
“AdBIOPRO is designed to build a foundation for an important Pharma 4.0 area for integrated and continuous bioproduction. This field is of strategic importance for the industry.”
”The high-quality science, education and competence sharing of AdBIOPRO are very relevant for Swedish industry and its international competitiveness, and for the society in large (patients, health system) as it facilitates for new biopharmaceuticals, produced more economically and more sustainably.”
”AdBIOPRO is one of very few academic centres in the world focusing on continuous bioproduction, and probably the only one with such a broadness of scope and collaborations. The Centre has developed collaborations nationally and internationally as shown by the number of contacts established with top academic institutions in Sweden and abroad and many companies.”
For more information about AdBIOPRO, please visit: https://www.kth.se/adbiopro.
For more information, please contact:
Laura Chirica, PhD
CEO Cellevate
Email: laura.chirica@cellevate.com
About Cellevate
Cellevate is a spin out from NanoLund – a world leading nanomaterial academic center. The company founded in 2014, develops and markets products based on a proprietary nanofiber-based platform – the Cellevat3d™ – a game-changing, green and sustainable, deep-tech innovation for the biopharmaceutical industry. This platform allows for an industrial-scale production of microcarriers with unparalleled surface area for cell growth, reproducibility and customization. Cellevat3d™ microcarriers products are designed for laboratory testing of cell lines as well as pilot and large-scale batch production of novel classes of biological therapies, including cell- and gene therapies and vaccines. Cellevat3d™ microcarriers have a commercial launch and sales start planned for 2024.
For more information, please visit www.cellevate.com.
